Exact Sciences to Meet with Medicare Reviewers on Cancer Test Coverage | GenomeWeb
NEW YORK (GenomeWeb News) – Exact Sciences will meet next week with officials from the Centers for Medicare and Medicaid Services to discuss the status of CMS’ review of the firm’s colorectal cancer screening technology, the company said today.
 
The company applied last August for a national coverage determination with CMS to try to get the stool-based CRC diagnostic covered under Medicare, but in October it was notified by the US Food and Drug Administration that the PreGen-Plus assay would require premarket approval.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.